Legend Biotech Announces Participation in Upcoming Investor Conferences

Feb 24, 2023

SOMERSET, N.J.— February 24, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences:

Event: Cowen 43rd Annual Healthcare Conference
Location: Boston, MA
Fireside Chat Date & Time: Tuesday, March 7, 2023 at 9:50am ET
Presenter: Ying Huang, Ph.D., CEO

Event: Barclays Global Healthcare Conference
Location: Miami, FL
Fireside Chat Date & Time: Tuesday, March 14, 2023 at 10:15am ET
Presenter: Ying Huang, Ph.D., CEO

– End –

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

Press Contact:

Tina Carter, Corporate Communications Lead, Legend Biotech

tina.carter@legendbiotech.com 

(908) 331-5025

Investor Contacts:

Joanne Choi, Senior Manager, Investor Relations, Legend Biotech

joanne.choi@legendbiotech.com

Crystal Chen, Manager, Investor Relations, Legend Biotech

crystal.chen@legendbiotech.com

Source: Legend Biotech

###

close

You are about to leave LegendBiotech.com

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.